igforum.bio / pfizer-says-covid-19-vaccine-list-price-could-be-130-per-dose-once-government-contracts-end-cnn-business - 66294
D
%Start Pfizer says Covid-19 vaccine list price could be $130 per dose once government contracts end   CNN - Business HEAD TOPICS 
 <h1>Pfizer says Covid-19 vaccine list price could be $130 per dose once government contracts end   CNN</h1>10/22/2022 5:46:00 AM
 <h2>Drugmaker Pfizer said that as government contracts come to an end  possibly by early next year  its Covid-19 vaccine will be sold for $110 to $130 per dose</h2>
 <h3>Business And İndustry Sectors  Business</h3> Source
 <h3> CNN </h3>
Drugmaker Pfizer said that as government contracts come to an end  possibly by early next year  its Covid-19 vaccine will be sold for $110 to $130 per dose
Drugmaker Pfizer said Friday that as government contracts come to an end, possibly by early next year, its Covid-19 vaccine will be sold for $110 to $130 per dose. This price model comes down to increased distribution costs as well as an expected shift from multidose vials to single-dose ones.(NVAX.the nation&#39;s free coronavirus vaccine program as pandemic response funding runs dry.The drugmaker laid out a potential price as it prepares to sell the shot commercially, perhaps early next year Pfizer said the earliest there could be a commercial rollout would be early next year.
%Start Pfizer says Covid-19 vaccine list price could be $130 per dose once government contracts end CNN - Business HEAD TOPICS

Pfizer says Covid-19 vaccine list price could be $130 per dose once government contracts end CNN

10/22/2022 5:46:00 AM

Drugmaker Pfizer said that as government contracts come to an end possibly by early next year its Covid-19 vaccine will be sold for $110 to $130 per dose

Business And İndustry Sectors Business

Source

CNN

Drugmaker Pfizer said that as government contracts come to an end possibly by early next year its Covid-19 vaccine will be sold for $110 to $130 per dose Drugmaker Pfizer said Friday that as government contracts come to an end, possibly by early next year, its Covid-19 vaccine will be sold for $110 to $130 per dose. This price model comes down to increased distribution costs as well as an expected shift from multidose vials to single-dose ones.(NVAX.the nation's free coronavirus vaccine program as pandemic response funding runs dry.The drugmaker laid out a potential price as it prepares to sell the shot commercially, perhaps early next year Pfizer said the earliest there could be a commercial rollout would be early next year.
thumb_up Like (15)
comment Reply (2)
share Share
visibility 269 views
thumb_up 15 likes
comment 2 replies
A
Audrey Mueller 2 minutes ago
This is the “commercial list price,” but the company says it does not anticipate that most peopl...
E
Elijah Patel 3 minutes ago
"We expect Moderna to adapt to this signal," SVB Securities analyst David Risinger said in...
E
This is the “commercial list price,” but the company says it does not anticipate that most people will have to pay out of pocket. It also pointed to its patient assistance program, which helps people without insurance get vaccines.
This is the “commercial list price,” but the company says it does not anticipate that most people will have to pay out of pocket. It also pointed to its patient assistance program, which helps people without insurance get vaccines.
thumb_up Like (12)
comment Reply (2)
thumb_up 12 likes
comment 2 replies
M
Madison Singh 5 minutes ago
"We expect Moderna to adapt to this signal," SVB Securities analyst David Risinger said in...
J
Joseph Kim 10 minutes ago
Wall Street was expecting such price hikes due to weak demand for COVID vaccines, which meant manufa...
J
&quot;We expect Moderna to adapt to this signal,&quot; SVB Securities analyst David Risinger said in a research note, adding that he sees Pfizer/BioNTech, Moderna and Novavax &quot;pricing in a similar range for the foreseeable future. For now, Covid-19 vaccines are still available for free.&quot; The outlet noted that Lukin did not say whether the company will make any accommodations for the tens of millions of people in the U. Pfizer says it anticipates that the Covid-19 vaccine pricing could come into play when the distribution and reimbursement of vaccines transition from government contracts to the traditional health-care system, as early as the first quarter of 2023.
"We expect Moderna to adapt to this signal," SVB Securities analyst David Risinger said in a research note, adding that he sees Pfizer/BioNTech, Moderna and Novavax "pricing in a similar range for the foreseeable future. For now, Covid-19 vaccines are still available for free." The outlet noted that Lukin did not say whether the company will make any accommodations for the tens of millions of people in the U. Pfizer says it anticipates that the Covid-19 vaccine pricing could come into play when the distribution and reimbursement of vaccines transition from government contracts to the traditional health-care system, as early as the first quarter of 2023.
thumb_up Like (10)
comment Reply (3)
thumb_up 10 likes
comment 3 replies
H
Hannah Kim 5 minutes ago
Wall Street was expecting such price hikes due to weak demand for COVID vaccines, which meant manufa...
O
Oliver Taylor 7 minutes ago
The People's Vaccine Alliance said in a statement Friday that Pfizer's planned price hike wo...
C
Wall Street was expecting such price hikes due to weak demand for COVID vaccines, which meant manufacturers would need to hike prices to meet revenue forecasts for 2023 and beyond. An analysis published by the Kaiser Family Foundation this week said that without additional funding or protections, the commercialization of Covid-19 preventative and countermeasures would create access barriers for vaccines, tests and therapeutics – especially for the uninsured and underinsured.S. Two key changes will lead to commercialization: the end of the US government’s public health emergency declaration and the depletion of federally purchased supply.S.
Wall Street was expecting such price hikes due to weak demand for COVID vaccines, which meant manufacturers would need to hike prices to meet revenue forecasts for 2023 and beyond. An analysis published by the Kaiser Family Foundation this week said that without additional funding or protections, the commercialization of Covid-19 preventative and countermeasures would create access barriers for vaccines, tests and therapeutics – especially for the uninsured and underinsured.S. Two key changes will lead to commercialization: the end of the US government’s public health emergency declaration and the depletion of federally purchased supply.S.
thumb_up Like (3)
comment Reply (2)
thumb_up 3 likes
comment 2 replies
M
Mia Anderson 10 minutes ago
The People's Vaccine Alliance said in a statement Friday that Pfizer's planned price hike wo...
A
Andrew Wilson 19 minutes ago
Neither change has come to pass; the public health emergency declaration was renewed last week for a...
W
The People&#39;s Vaccine Alliance said in a statement Friday that Pfizer&#39;s planned price hike would amount to a 10,000% markup above the cost of producing the vaccine, which is to be as low as $1. Each change creates its own challenges and, taken together, “may amplify access challenges,” the analysis says.
The People's Vaccine Alliance said in a statement Friday that Pfizer's planned price hike would amount to a 10,000% markup above the cost of producing the vaccine, which is to be as low as $1. Each change creates its own challenges and, taken together, “may amplify access challenges,” the analysis says.
thumb_up Like (0)
comment Reply (0)
thumb_up 0 likes
L
Neither change has come to pass; the public health emergency declaration was renewed last week for another 90 days. Around 19. But Congress has yet to act on the Biden administration’s request for billions more in funding to ensure a steady and accessible supply of Covid-19 countermeasures.S.
Neither change has come to pass; the public health emergency declaration was renewed last week for another 90 days. Around 19. But Congress has yet to act on the Biden administration’s request for billions more in funding to ensure a steady and accessible supply of Covid-19 countermeasures.S.
thumb_up Like (3)
comment Reply (2)
thumb_up 3 likes
comment 2 replies
V
Victoria Lopez 3 minutes ago
A large portion of the government’s request for further Covid-19 funding is a “critical request�...
C
Charlotte Lee 9 minutes ago
The goal is to avoid a situation like last winter when there was a test shortage due to lack of anti...
I
A large portion of the government’s request for further Covid-19 funding is a “critical request” for resources to support development of new vaccines and treatments that can withstand future variants of the coronavirus, said Dawn O’Connell, assistant secretary for preparedness and response within the US Department of Health and Human Services. In the first seven weeks of the 2021 revaccination campaign, over 27 million people received their third shot even though only older and immunocompromised people were eligible at that point. “That would get us out of the boom-bust cycle surge in cases,” she said at a news briefing Wednesday hosted by KFF.
A large portion of the government’s request for further Covid-19 funding is a “critical request” for resources to support development of new vaccines and treatments that can withstand future variants of the coronavirus, said Dawn O’Connell, assistant secretary for preparedness and response within the US Department of Health and Human Services. In the first seven weeks of the 2021 revaccination campaign, over 27 million people received their third shot even though only older and immunocompromised people were eligible at that point. “That would get us out of the boom-bust cycle surge in cases,” she said at a news briefing Wednesday hosted by KFF.
thumb_up Like (14)
comment Reply (3)
thumb_up 14 likes
comment 3 replies
J
James Smith 10 minutes ago
The goal is to avoid a situation like last winter when there was a test shortage due to lack of anti...
D
Daniel Kumar 8 minutes ago
But treatments and tests would face the “most acute” challenges, with cost sharing that would af...
E
The goal is to avoid a situation like last winter when there was a test shortage due to lack of anticipation for the Delta variant, said Jen Kates, senior vice president and director of global health &amp;amp; HIV policy with KFF.com Register Reporting by Michael Erman; Editing by Andrea Ricci and Bill Berkrot Our Standards:.&quot;This latest obscene price hike is truly a mask-off moment for one of the great profiteers of this pandemic. Another portion of the funding would go toward protecting the uninsured and ensuring universal access to Covid-19 countermeasures, O’Connell said. According to the KFF analysis, once the measures are commercialized, uninsured adults would lose access to free vaccines.
The goal is to avoid a situation like last winter when there was a test shortage due to lack of anticipation for the Delta variant, said Jen Kates, senior vice president and director of global health &amp; HIV policy with KFF.com Register Reporting by Michael Erman; Editing by Andrea Ricci and Bill Berkrot Our Standards:."This latest obscene price hike is truly a mask-off moment for one of the great profiteers of this pandemic. Another portion of the funding would go toward protecting the uninsured and ensuring universal access to Covid-19 countermeasures, O’Connell said. According to the KFF analysis, once the measures are commercialized, uninsured adults would lose access to free vaccines.
thumb_up Like (23)
comment Reply (0)
thumb_up 23 likes
D
But treatments and tests would face the “most acute” challenges, with cost sharing that would affect how much of the cost would be covered by insurance. &quot;This is daylight robbery,&quot; Kosgei said of the coming price increase.
But treatments and tests would face the “most acute” challenges, with cost sharing that would affect how much of the cost would be covered by insurance. "This is daylight robbery," Kosgei said of the coming price increase.
thumb_up Like (46)
comment Reply (2)
thumb_up 46 likes
comment 2 replies
C
Charlotte Lee 2 minutes ago
Transitioning to commercialization was always part of the plan, O’Connell said. It’s the way oth...
D
Daniel Kumar 8 minutes ago
“But the process is complex,” she said."Right now, people in developing countries are dying...
S
Transitioning to commercialization was always part of the plan, O’Connell said. It’s the way other health conditions are approached in the US.
Transitioning to commercialization was always part of the plan, O’Connell said. It’s the way other health conditions are approached in the US.
thumb_up Like (43)
comment Reply (2)
thumb_up 43 likes
comment 2 replies
L
Liam Wilson 18 minutes ago
“But the process is complex,” she said."Right now, people in developing countries are dying...
K
Kevin Wang 8 minutes ago
Part of the Covid request makes this a little less bumpy. ” ." Related Content....
E
“But the process is complex,” she said.&quot;Right now, people in developing countries are dying without access to Paxlovid, an antiviral Covid-19 treatment for which Pfizer is charging hundreds of dollars per course. “Regardless of whether we were going to get Covid funding, we were eventually going to have to make this transition at some point.
“But the process is complex,” she said."Right now, people in developing countries are dying without access to Paxlovid, an antiviral Covid-19 treatment for which Pfizer is charging hundreds of dollars per course. “Regardless of whether we were going to get Covid funding, we were eventually going to have to make this transition at some point.
thumb_up Like (1)
comment Reply (1)
thumb_up 1 likes
comment 1 replies
C
Charlotte Lee 27 minutes ago
Part of the Covid request makes this a little less bumpy. ” ." Related Content....
S
Part of the Covid request makes this a little less bumpy. ” .&quot; Related Content.
Part of the Covid request makes this a little less bumpy. ” ." Related Content.
thumb_up Like (12)
comment Reply (2)
thumb_up 12 likes
comment 2 replies
H
Henry Schmidt 1 minutes ago
Read more:
CNN » Pfizer COVID vaccine price hike seen giving revenue boost for years 'Dayli...
Z
Zoe Mueller 7 minutes ago
Categories: Entertainment, KUSI, Local San Diego News, Sports, Trending Read more >> 2 new aggressiv...
C
Read more:<br>CNN &raquo; Pfizer COVID vaccine price hike seen giving revenue boost for years 'Daylight Robbery': Pfizer Condemned for Hiking US Covid Vaccine Price by 10,000% Above Cost Pfizer Targets Covid Vaccine Price of at Least $110 a Dose Pfizer will start charging $110-$130 a dose for COVID vaccines next year 
 <h3>Padres talk with Baseball Hall of Famer Dave Winfield -</h3>
SAN DIEGO (KUSI) – The Padres are in the National League Championship Series for the first time since 1998, and San Diego is buzzing with excitement. KUSI’s Lauren Phinney got to speak with baseball Hall of Famer Dave Winfield to talk about the Padres prospects of further success this season.
Read more:
CNN » Pfizer COVID vaccine price hike seen giving revenue boost for years 'Daylight Robbery': Pfizer Condemned for Hiking US Covid Vaccine Price by 10,000% Above Cost Pfizer Targets Covid Vaccine Price of at Least $110 a Dose Pfizer will start charging $110-$130 a dose for COVID vaccines next year

Padres talk with Baseball Hall of Famer Dave Winfield -

SAN DIEGO (KUSI) – The Padres are in the National League Championship Series for the first time since 1998, and San Diego is buzzing with excitement. KUSI’s Lauren Phinney got to speak with baseball Hall of Famer Dave Winfield to talk about the Padres prospects of further success this season.
thumb_up Like (31)
comment Reply (2)
thumb_up 31 likes
comment 2 replies
E
Ethan Thomas 31 minutes ago
Categories: Entertainment, KUSI, Local San Diego News, Sports, Trending Read more >> 2 new aggressiv...
Z
Zoe Mueller 43 minutes ago
go get boosted and enjoy Good for them. Take advantage of the saps....
H
Categories: Entertainment, KUSI, Local San Diego News, Sports, Trending Read more >> 2 new aggressive strains were just announced for winter. &#129318;&#127995; For the fake juice if u dont know it&#39;s a scam yet, then idk what to tell u.
Categories: Entertainment, KUSI, Local San Diego News, Sports, Trending Read more >> 2 new aggressive strains were just announced for winter. 🤦🏻 For the fake juice if u dont know it's a scam yet, then idk what to tell u.
thumb_up Like (37)
comment Reply (3)
thumb_up 37 likes
comment 3 replies
E
Ethan Thomas 4 minutes ago
go get boosted and enjoy Good for them. Take advantage of the saps....
B
Brandon Kumar 12 minutes ago
Just in time for the school mandates 🤔 Let the poor/uninsured suffer. A classic. Who cares....
Z
go get boosted and enjoy Good for them. Take advantage of the saps.
go get boosted and enjoy Good for them. Take advantage of the saps.
thumb_up Like (15)
comment Reply (1)
thumb_up 15 likes
comment 1 replies
S
Sophie Martin 45 minutes ago
Just in time for the school mandates 🤔 Let the poor/uninsured suffer. A classic. Who cares....
N
Just in time for the school mandates &#129300; Let the poor/uninsured suffer. A classic. Who cares.
Just in time for the school mandates 🤔 Let the poor/uninsured suffer. A classic. Who cares.
thumb_up Like (14)
comment Reply (0)
thumb_up 14 likes
C
They’re worthless for 98% of the population. Nationalize them COVID-19 pandemic won&#39;t end because a lot of money is being made &#128064; They gonna have to come up with something new now!
They’re worthless for 98% of the population. Nationalize them COVID-19 pandemic won't end because a lot of money is being made 👀 They gonna have to come up with something new now!
thumb_up Like (50)
comment Reply (3)
thumb_up 50 likes
comment 3 replies
S
Sophie Martin 5 minutes ago
The board will expect bigger bonuses! That’s expensive for something that doesn’t work past a mo...
A
Aria Nguyen 6 minutes ago
prices for its COVID-19 vaccines going forward could spur revenue for years, analysts said. If y’a...
N
The board will expect bigger bonuses! That’s expensive for something that doesn’t work past a month or two
Pfizer COVID vaccine price hike seen giving revenue boost for yearsPfizer&#39;s plan to as much as quadruple current U.S.
The board will expect bigger bonuses! That’s expensive for something that doesn’t work past a month or two Pfizer COVID vaccine price hike seen giving revenue boost for yearsPfizer's plan to as much as quadruple current U.S.
thumb_up Like (27)
comment Reply (3)
thumb_up 27 likes
comment 3 replies
G
Grace Liu 4 minutes ago
prices for its COVID-19 vaccines going forward could spur revenue for years, analysts said. If y’a...
M
Mia Anderson 12 minutes ago
Who TF would ever want to pay to get no protection what so ever and develop heart problems and clogg...
E
prices for its COVID-19 vaccines going forward could spur revenue for years, analysts said. If y’all wanna waste $130, you can just send it to my cash app.
prices for its COVID-19 vaccines going forward could spur revenue for years, analysts said. If y’all wanna waste $130, you can just send it to my cash app.
thumb_up Like (27)
comment Reply (3)
thumb_up 27 likes
comment 3 replies
E
Ella Rodriguez 32 minutes ago
Who TF would ever want to pay to get no protection what so ever and develop heart problems and clogg...
D
Daniel Kumar 34 minutes ago
Wow! Can’t wait to see the comments about this! Feel bad for the people who think this thing helps...
M
Who TF would ever want to pay to get no protection what so ever and develop heart problems and clogged arteries &#128514;&#128128; $cience Lol capitalism sucks &#129488; Haha. And it will be a hard pass for me.
Who TF would ever want to pay to get no protection what so ever and develop heart problems and clogged arteries 😂💀 $cience Lol capitalism sucks 🧐 Haha. And it will be a hard pass for me.
thumb_up Like (11)
comment Reply (0)
thumb_up 11 likes
E
Wow! Can’t wait to see the comments about this! Feel bad for the people who think this thing helps
Wonder how much they charged the government per dose Biggest Corporate greed scam!
Wow! Can’t wait to see the comments about this! Feel bad for the people who think this thing helps Wonder how much they charged the government per dose Biggest Corporate greed scam!
thumb_up Like (40)
comment Reply (2)
thumb_up 40 likes
comment 2 replies
A
Aria Nguyen 43 minutes ago
'Daylight Robbery': Pfizer Condemned for Hiking US Covid Vaccine Price by 10,000% Above Cost...
S
Sofia Garcia 31 minutes ago
government stops purchases Talk about deterrence. I'm interested in how much Novavax will be....
K
&#39;Daylight Robbery&#39;: Pfizer Condemned for Hiking US Covid Vaccine Price by 10,000% Above Cost\u0022While health workers and the vulnerable continue to go unvaccinated in developing countries, Pfizer is shamelessly fleecing the public for ever-greater sums of money,\u0022 said one campaigner. Making it both expensive and useless. Pfi$er
Pfizer Targets Covid Vaccine Price of at Least $110 a DosePfizer said it expects to price its Covid-19 vaccine at $110 to $130 a dose for adults when the U.S.
'Daylight Robbery': Pfizer Condemned for Hiking US Covid Vaccine Price by 10,000% Above Cost\u0022While health workers and the vulnerable continue to go unvaccinated in developing countries, Pfizer is shamelessly fleecing the public for ever-greater sums of money,\u0022 said one campaigner. Making it both expensive and useless. Pfi$er Pfizer Targets Covid Vaccine Price of at Least $110 a DosePfizer said it expects to price its Covid-19 vaccine at $110 to $130 a dose for adults when the U.S.
thumb_up Like (35)
comment Reply (1)
thumb_up 35 likes
comment 1 replies
Z
Zoe Mueller 1 minutes ago
government stops purchases Talk about deterrence. I'm interested in how much Novavax will be....
D
government stops purchases Talk about deterrence. I&#39;m interested in how much Novavax will be.
government stops purchases Talk about deterrence. I'm interested in how much Novavax will be.
thumb_up Like (42)
comment Reply (0)
thumb_up 42 likes
N
They have been working on a new strain of Covid? Because this “vaccine” is worthless.
They have been working on a new strain of Covid? Because this “vaccine” is worthless.
thumb_up Like (48)
comment Reply (2)
thumb_up 48 likes
comment 2 replies
E
Ethan Thomas 37 minutes ago
Pfizer will start charging $110-$130 a dose for COVID vaccines next yearPfizer plans to charge $110 ...
A
Alexander Wang 15 minutes ago
This is the end times. Phizer needs to adopt a Costco style return policy And in Australia, we'l...
A
Pfizer will start charging $110-$130 a dose for COVID vaccines next yearPfizer plans to charge $110 to $130 per dose for its COVID-19 vaccine once government purchases end next year. Americans are enthusiastic about being literal property of big pharmaceutical companies and paypigs to their government.
Pfizer will start charging $110-$130 a dose for COVID vaccines next yearPfizer plans to charge $110 to $130 per dose for its COVID-19 vaccine once government purchases end next year. Americans are enthusiastic about being literal property of big pharmaceutical companies and paypigs to their government.
thumb_up Like (40)
comment Reply (2)
thumb_up 40 likes
comment 2 replies
I
Isaac Schmidt 36 minutes ago
This is the end times. Phizer needs to adopt a Costco style return policy And in Australia, we'l...
L
Lily Watson 117 minutes ago
America needs a revolution. Pfizer says COVID-19 vaccine will cost $110-$130 per dosePfizer will cha...
O
This is the end times. Phizer needs to adopt a Costco style return policy And in Australia, we&#39;ll still be paying nothing.
This is the end times. Phizer needs to adopt a Costco style return policy And in Australia, we'll still be paying nothing.
thumb_up Like (37)
comment Reply (1)
thumb_up 37 likes
comment 1 replies
Z
Zoe Mueller 26 minutes ago
America needs a revolution. Pfizer says COVID-19 vaccine will cost $110-$130 per dosePfizer will cha...
I
America needs a revolution. Pfizer says COVID-19 vaccine will cost $110-$130 per dosePfizer will charge $110 to $130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots
Pfizer reportedly plans to charge up to $130 for COVID-19 vaccinePfizer said it would charge between $110 and $130 for its mRNA vaccine after the government stops paying for them.
America needs a revolution. Pfizer says COVID-19 vaccine will cost $110-$130 per dosePfizer will charge $110 to $130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots Pfizer reportedly plans to charge up to $130 for COVID-19 vaccinePfizer said it would charge between $110 and $130 for its mRNA vaccine after the government stops paying for them.
thumb_up Like (40)
comment Reply (1)
thumb_up 40 likes
comment 1 replies
L
Liam Wilson 79 minutes ago
That will happen once the public health emergency put in place at the start of the COVID-19 pandemic...
T
That will happen once the public health emergency put in place at the start of the COVID-19 pandemic is ended. What “protection” exactly? &#129318;‍&#129318;‍ But it doesn&#39;t work A sucker is born every minute.
That will happen once the public health emergency put in place at the start of the COVID-19 pandemic is ended. What “protection” exactly? 🤦‍🤦‍ But it doesn't work A sucker is born every minute.
thumb_up Like (47)
comment Reply (3)
thumb_up 47 likes
comment 3 replies
C
Christopher Lee 108 minutes ago
This price model comes down to increased distribution costs as well as an expected shift from multid...
L
Luna Park 28 minutes ago
"We expect Moderna to adapt to this signal," SVB Securities analyst David Risinger said in...
K
This price model comes down to increased distribution costs as well as an expected shift from multidose vials to single-dose ones.(NVAX.the nation&#39;s free coronavirus vaccine program as pandemic response funding runs dry.The drugmaker laid out a potential price as it prepares to sell the shot commercially, perhaps early next year Pfizer said the earliest there could be a commercial rollout would be early next year. This is the “commercial list price,” but the company says it does not anticipate that most people will have to pay out of pocket. It also pointed to its patient assistance program, which helps people without insurance get vaccines.
This price model comes down to increased distribution costs as well as an expected shift from multidose vials to single-dose ones.(NVAX.the nation's free coronavirus vaccine program as pandemic response funding runs dry.The drugmaker laid out a potential price as it prepares to sell the shot commercially, perhaps early next year Pfizer said the earliest there could be a commercial rollout would be early next year. This is the “commercial list price,” but the company says it does not anticipate that most people will have to pay out of pocket. It also pointed to its patient assistance program, which helps people without insurance get vaccines.
thumb_up Like (6)
comment Reply (3)
thumb_up 6 likes
comment 3 replies
L
Lily Watson 16 minutes ago
"We expect Moderna to adapt to this signal," SVB Securities analyst David Risinger said in...
A
Alexander Wang 41 minutes ago
Wall Street was expecting such price hikes due to weak demand for COVID vaccines, which meant manufa...
L
&quot;We expect Moderna to adapt to this signal,&quot; SVB Securities analyst David Risinger said in a research note, adding that he sees Pfizer/BioNTech, Moderna and Novavax &quot;pricing in a similar range for the foreseeable future. For now, Covid-19 vaccines are still available for free.&quot; The outlet noted that Lukin did not say whether the company will make any accommodations for the tens of millions of people in the U. Pfizer says it anticipates that the Covid-19 vaccine pricing could come into play when the distribution and reimbursement of vaccines transition from government contracts to the traditional health-care system, as early as the first quarter of 2023.
"We expect Moderna to adapt to this signal," SVB Securities analyst David Risinger said in a research note, adding that he sees Pfizer/BioNTech, Moderna and Novavax "pricing in a similar range for the foreseeable future. For now, Covid-19 vaccines are still available for free." The outlet noted that Lukin did not say whether the company will make any accommodations for the tens of millions of people in the U. Pfizer says it anticipates that the Covid-19 vaccine pricing could come into play when the distribution and reimbursement of vaccines transition from government contracts to the traditional health-care system, as early as the first quarter of 2023.
thumb_up Like (40)
comment Reply (0)
thumb_up 40 likes
A
Wall Street was expecting such price hikes due to weak demand for COVID vaccines, which meant manufacturers would need to hike prices to meet revenue forecasts for 2023 and beyond. An analysis published by the Kaiser Family Foundation this week said that without additional funding or protections, the commercialization of Covid-19 preventative and countermeasures would create access barriers for vaccines, tests and therapeutics – especially for the uninsured and underinsured.S. Two key changes will lead to commercialization: the end of the US government’s public health emergency declaration and the depletion of federally purchased supply.S.
Wall Street was expecting such price hikes due to weak demand for COVID vaccines, which meant manufacturers would need to hike prices to meet revenue forecasts for 2023 and beyond. An analysis published by the Kaiser Family Foundation this week said that without additional funding or protections, the commercialization of Covid-19 preventative and countermeasures would create access barriers for vaccines, tests and therapeutics – especially for the uninsured and underinsured.S. Two key changes will lead to commercialization: the end of the US government’s public health emergency declaration and the depletion of federally purchased supply.S.
thumb_up Like (42)
comment Reply (0)
thumb_up 42 likes
A
The People&#39;s Vaccine Alliance said in a statement Friday that Pfizer&#39;s planned price hike would amount to a 10,000% markup above the cost of producing the vaccine, which is to be as low as $1. Each change creates its own challenges and, taken together, “may amplify access challenges,” the analysis says.
The People's Vaccine Alliance said in a statement Friday that Pfizer's planned price hike would amount to a 10,000% markup above the cost of producing the vaccine, which is to be as low as $1. Each change creates its own challenges and, taken together, “may amplify access challenges,” the analysis says.
thumb_up Like (2)
comment Reply (3)
thumb_up 2 likes
comment 3 replies
S
Sophia Chen 13 minutes ago
Neither change has come to pass; the public health emergency declaration was renewed last week for a...
E
Elijah Patel 108 minutes ago
A large portion of the government’s request for further Covid-19 funding is a “critical request�...
J
Neither change has come to pass; the public health emergency declaration was renewed last week for another 90 days. Around 19. But Congress has yet to act on the Biden administration’s request for billions more in funding to ensure a steady and accessible supply of Covid-19 countermeasures.S.
Neither change has come to pass; the public health emergency declaration was renewed last week for another 90 days. Around 19. But Congress has yet to act on the Biden administration’s request for billions more in funding to ensure a steady and accessible supply of Covid-19 countermeasures.S.
thumb_up Like (32)
comment Reply (0)
thumb_up 32 likes
M
A large portion of the government’s request for further Covid-19 funding is a “critical request” for resources to support development of new vaccines and treatments that can withstand future variants of the coronavirus, said Dawn O’Connell, assistant secretary for preparedness and response within the US Department of Health and Human Services. In the first seven weeks of the 2021 revaccination campaign, over 27 million people received their third shot even though only older and immunocompromised people were eligible at that point. “That would get us out of the boom-bust cycle surge in cases,” she said at a news briefing Wednesday hosted by KFF.
A large portion of the government’s request for further Covid-19 funding is a “critical request” for resources to support development of new vaccines and treatments that can withstand future variants of the coronavirus, said Dawn O’Connell, assistant secretary for preparedness and response within the US Department of Health and Human Services. In the first seven weeks of the 2021 revaccination campaign, over 27 million people received their third shot even though only older and immunocompromised people were eligible at that point. “That would get us out of the boom-bust cycle surge in cases,” she said at a news briefing Wednesday hosted by KFF.
thumb_up Like (28)
comment Reply (3)
thumb_up 28 likes
comment 3 replies
L
Lucas Martinez 12 minutes ago
The goal is to avoid a situation like last winter when there was a test shortage due to lack of anti...
Z
Zoe Mueller 28 minutes ago
According to the KFF analysis, once the measures are commercialized, uninsured adults would lose acc...
S
The goal is to avoid a situation like last winter when there was a test shortage due to lack of anticipation for the Delta variant, said Jen Kates, senior vice president and director of global health &amp;amp; HIV policy with KFF.com Register Reporting by Michael Erman; Editing by Andrea Ricci and Bill Berkrot Our Standards:.&quot;This latest obscene price hike is truly a mask-off moment for one of the great profiteers of this pandemic. Another portion of the funding would go toward protecting the uninsured and ensuring universal access to Covid-19 countermeasures, O’Connell said.
The goal is to avoid a situation like last winter when there was a test shortage due to lack of anticipation for the Delta variant, said Jen Kates, senior vice president and director of global health &amp; HIV policy with KFF.com Register Reporting by Michael Erman; Editing by Andrea Ricci and Bill Berkrot Our Standards:."This latest obscene price hike is truly a mask-off moment for one of the great profiteers of this pandemic. Another portion of the funding would go toward protecting the uninsured and ensuring universal access to Covid-19 countermeasures, O’Connell said.
thumb_up Like (46)
comment Reply (1)
thumb_up 46 likes
comment 1 replies
R
Ryan Garcia 83 minutes ago
According to the KFF analysis, once the measures are commercialized, uninsured adults would lose acc...
J
According to the KFF analysis, once the measures are commercialized, uninsured adults would lose access to free vaccines. But treatments and tests would face the “most acute” challenges, with cost sharing that would affect how much of the cost would be covered by insurance. &quot;This is daylight robbery,&quot; Kosgei said of the coming price increase.
According to the KFF analysis, once the measures are commercialized, uninsured adults would lose access to free vaccines. But treatments and tests would face the “most acute” challenges, with cost sharing that would affect how much of the cost would be covered by insurance. "This is daylight robbery," Kosgei said of the coming price increase.
thumb_up Like (7)
comment Reply (2)
thumb_up 7 likes
comment 2 replies
I
Isaac Schmidt 35 minutes ago
Transitioning to commercialization was always part of the plan, O’Connell said. It’s the way oth...
O
Oliver Taylor 12 minutes ago
“But the process is complex,” she said."Right now, people in developing countries are dying...
H
Transitioning to commercialization was always part of the plan, O’Connell said. It’s the way other health conditions are approached in the US.
Transitioning to commercialization was always part of the plan, O’Connell said. It’s the way other health conditions are approached in the US.
thumb_up Like (34)
comment Reply (2)
thumb_up 34 likes
comment 2 replies
V
Victoria Lopez 6 minutes ago
“But the process is complex,” she said."Right now, people in developing countries are dying...
A
Audrey Mueller 18 minutes ago
” ." Related Content....
C
“But the process is complex,” she said.&quot;Right now, people in developing countries are dying without access to Paxlovid, an antiviral Covid-19 treatment for which Pfizer is charging hundreds of dollars per course. “Regardless of whether we were going to get Covid funding, we were eventually going to have to make this transition at some point. Part of the Covid request makes this a little less bumpy.
“But the process is complex,” she said."Right now, people in developing countries are dying without access to Paxlovid, an antiviral Covid-19 treatment for which Pfizer is charging hundreds of dollars per course. “Regardless of whether we were going to get Covid funding, we were eventually going to have to make this transition at some point. Part of the Covid request makes this a little less bumpy.
thumb_up Like (20)
comment Reply (2)
thumb_up 20 likes
comment 2 replies
A
Aria Nguyen 73 minutes ago
” ." Related Content....
R
Ryan Garcia 53 minutes ago
Pfizer says Covid-19 vaccine list price could be $130 per dose once government contracts end CNN -...
S
” .&quot; Related Content.
” ." Related Content.
thumb_up Like (36)
comment Reply (0)
thumb_up 36 likes

Write a Reply